This announcement is a separate document:
三生製藥:業務發展最新情況 - 就百泌達及百達揚與阿斯利康簽訂獨家許可協議
3SBIO: BUSINESS UPDATE - EXCLUSIVE LICENSE AGREEMENT WITH ASTRAZENECA IN RESPECT OF BYETTA AND BYDUREON
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.